Inventiva S.A.
IVAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Inventiva S.A. focuses on Biotechnology services and products. Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). With a market capitalization of $1.09B, it sits in small-cap territory. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses.
Market Cap
$1.09B
Beta
0.88
P/E (TTM)
—
P/E (Fwd)
-5.73
EPS (TTM)
$-2.21
EPS (Fwd)
$-0.91
ROE
—
ROA
-45.1%
Cash
$99.8M
Total Debt
$230.9M
Free CF
-$200.7M
52W Change
54.3%
Annual Financials
Cash vs Debt
The company holds $99.8M in cash, though total debt stands at $230.9M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$200.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has pulled back from $12.2M (2022) to $4.5M (2025), a 63% decline worth watching.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing IVA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.